ReviewCell communication and signaling : CCS2023
Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions.
Review in Cell communication and signaling : CCS, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 49 citations in OpenAlex.
- GenoGlyph: Pan-cancer genomic mutation inference and risk stratification from diagnostic histopathology slides.Research square · 2026Article
- Continuous multi-omics pathway enrichment analysis resolves hidden functional heterogeneity.Briefings in bioinformatics · 2026Article
- Tumor cell intrinsic mechanisms of immune escape.Cell communication and signaling : CCS · 2026Review
- The landscape of responses to neoadjuvant immunotherapy in resectable Kirsten rat sarcoma viral oncogene homolog-mutant lung adenocarcinoma: Clinical heterogeneity and correlative immunologic analysis.Clinical and translational medicine · 2026Article
- UnlockingCurrent oncology (Toronto, Ont.) · 2026Review
- Chemoresistance in the era of immunotherapy: challenges and novel combinatorial strategies for digestive system tumors.Frontiers in immunology · 2026Review
- Understanding cancer as a systemic disease through comprehension of neural stemness as the core property of cancer cell and the basic rules it dictates.Frontiers in cell and developmental biology · 2026Review
- Genomic alteration correlates with programmed cell death ligand 1 (PD-L1) expression in 2750 Chinese non-small-cell lung cancer patients.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Single-cell and spatial transcriptome profiling identifies the immunosuppressive spatial niche inJournal for immunotherapy of cancer · 2025Article
- Prolonged response to dual immune checkpoint blockade in patients with advanced solid tumors: a case series.NPJ precision oncology · 2025Article
- Monotherapy With Immune Checkpoint Blockade Improves Survival Outcomes in KRAS-Mutant but Not KRAS Wild-Type Metastatic Lung Adenocarcinoma: Validation From an Extended Swedish Cohort.JTO clinical and research reports · 2025Article
- Bioenergetic Model of Retrotransposon Activity in Cancer Cells.Life (Basel, Switzerland) · 2025Article
- KRAS amplification in colorectal cancer: correlations with clinicopathological features and prognosis in patients and prediction of response to targeted therapy.Journal of translational medicine · 2025Article
- High-Throughput Targeted Drug Screening for NF1-associated High-Grade Gliomas with ATRX Deficiency.bioRxiv : the preprint server for biology · 2025Article
- Melatonin suppresses PD-L1 expression and exerts antitumor activity in hepatocellular carcinoma.Scientific reports · 2025Article
- Breaking barriers: we need a multidisciplinary approach to tackle cancer drug resistance.BJC reports · 2025Review
- Divergent roles of PKM2 in regulating PD-L1 and PD-L2 expression and their implications in human and mouse cancer models.Acta biochimica et biophysica Sinica · 2025Article
- Elevated plasma levels of WAP four-disulfide core domain 2 as a potential prognostic biomarker for various cancers.Frontiers in oncology · 2025Article
- Luteolin: exploring its therapeutic potential and molecular mechanisms in pulmonary diseases.Frontiers in pharmacology · 2025Review
- Senescence-associated secretory phenotype in lung cancer: remodeling the tumor microenvironment for metastasis and immune suppression.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Oncogenic driver mutations have implications that extend beyond cancer cells themselves. Aberrant tumour cell signalling has various effects on the tumour microenvironment and anti-tumour immunity, with important consequences for therapy response and resistance. We provide an overview of how mutant RAS, one of the most prevalent oncogenic drivers in cancer, can instigate immune evasion programs at the tumour cell level and through remodelling interactions with the innate and adaptive immune cell compartments. Finally, we describe how immune evasion networks focused on RAS, and the immune checkpoint molecule PD-L1 can be disrupted through therapeutic intervention, and discuss potential strategies for combinatorial treatment. Video abstract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.